The company’s strategic regulatory moves, such as the new FDA filing for Dato-Dxd, further bolster its future prospects. Despite some upcoming challenges, AstraZeneca’s solid business momentum, ...
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
This optimism is further supported by the company’s strategic decision to resubmit a Biologics License Application for Dato-DXd in EGFR+ NSCLC, backed by promising trial data. These factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback